EGLN3 and nonpapillary renal cell carcinoma: Deletion of the EGLN3 gene using CRISPR/Cas9, further interrogation of the PHD3/EGFR signaling axis, and evaluation of the effects of PHD3 knockdown on metastatic progression in orthotopic ccRCC animal models could further clarify PHD3′s role in this disease.